Accuray Incorp Stock Price, News & Analysis

Accuray reported its fiscal 2025 third quarter results, showing notable improvements in financial performance. The company achieved total net revenue of $113.2 million, marking a 12% increase year-over-year. The quarter saw reduced losses, with net loss decreasing to $1.3 million compared to $6.3 million in the prior year.

Key financial highlights include:

• Product revenue increased 16% to $57.3 million
• Service revenue grew 9% to $55.9 million
• Adjusted EBITDA improved to $6.0 million from $1.1 million
• Cash position strengthened to $78.8 million

Despite facing tariff challenges, the company maintained resilient performance. However, order backlog decreased 10% to $452.4 million. For fiscal year 2025, Accuray reaffirmed its adjusted EBITDA guidance of $28.5-31.0 million but adjusted revenue guidance to $452-460 million due to tariff impacts on product volume.

Accuray (NASDAQ: ARAY) has announced it will release its third quarter fiscal 2025 financial results on April 30, 2025. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on the same day to discuss the results for the quarter ended March 31, 2025.

Investors can access the conference call via USA dial-in (1-833-316-0563) or international dial-in (1-412-317-5747). A replay will be available for one week through 1-877-344-7529 (USA) or 1-412-317-0088 (international) using conference ID 8141169. Additionally, a live webcast will be accessible through the company's Investor Relations website at investors.accuray.com, with the replay available until Q4 FY2025 results announcement.

Accuray (NASDAQ: ARAY) presented new clinical data for its CyberKnife® System at the 2025 Radiosurgery Society Scientific Meeting, demonstrating its effectiveness in treating central nervous system tumors. Key findings include:

- A 25-year study showed 89.3% local control rate and 97.1% overall survival for vestibular schwannoma treatments

- Donut-shaped circumferential SBRT proved safe and effective for spinal metastases

- In elderly patients with trigeminal neuralgia, 90% experienced pain improvement or elimination

- For occipital condyle metastasis, the treatment achieved 93.8% local tumor control over three years, with 87.5% of patients experiencing pain relief

The CyberKnife System utilizes image guidance during treatment, leveraging up to 1,000 different beam angles and Synchrony® adaptive delivery technology to adjust for tumor or patient motion in real-time.

Accuray (NASDAQ: ARAY) has announced its participation in the 37th Annual Roth Conference scheduled for March 16-18, 2025, in Dana Point, California. The company's management will engage in a fireside chat on March 18, 2025, at 9:30am PT / 12:30pm ET, and will be available for one-on-one investor meetings.

A live webcast of the fireside chat will be accessible through their website at investors.accuray.com, with replay available for 90 days after the presentation. Accuray, headquartered in Madison, Wisconsin, specializes in radiation therapy solutions for oncology and neuro-radiosurgery, focusing on developing innovative treatments for complex cases while simplifying common procedures.

Accuray (NASDAQ: ARAY) reported strong fiscal Q2 2025 results with total net revenue of $116.2 million, an 8% year-over-year increase. The company achieved a net income of $2.5 million compared to a $9.6 million loss in the prior year period. Product revenue increased 19% to $61.2 million, while service revenue slightly decreased by 1% to $55.0 million.

Gross profit improved to $41.9 million (36.1% of revenue) from $35.9 million (33.5%) year-over-year. Operating expenses decreased 7% to $37.2 million. The company's adjusted EBITDA reached $9.6 million, up from $2.0 million in the prior year. Based on strong performance, Accuray raised its fiscal year 2025 guidance, projecting revenue between $463-475 million and adjusted EBITDA of $28.5-31.0 million.

Accuray (NASDAQ: ARAY) announced a significant milestone as Shandong Cancer Hospital and Institute completed treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System, a product built in China through the CNNC-Accuray joint venture. The hospital, which was the first in China to receive the system, can now treat an average of 95 patient treatment fractions daily.

This achievement is particularly significant given China's projected increase in cancer cases, with expectations of 7.1 million diagnoses by 2045, up from 4.8 million in 2022 - a 47% increase. The Tomo C System, based on the helical TomoTherapy® platform, is designed to provide ultra-precise treatments while enabling higher patient throughput, addressing the growing needs of China's underserved radiation therapy market.

Accuray (NASDAQ: ARAY) has announced it will release its second quarter fiscal 2025 financial results on February 5, 2025. The company will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on the same day to discuss the results for the period ended December 31, 2024.

Investors can access the conference call via telephone at (833) 316-0563 (USA) or (412) 317-5747 (international). A replay will be available for one week at 1-877-344-7529 (USA) or 1-412-317-0088 (international) using conference ID 8496951. Additionally, a live webcast will be available through the company's Investor Relations website, with a replay accessible until the third quarter fiscal 2025 results announcement.

Accuray (NASDAQ: ARAY) has announced the appointment of Leonel Peralta as Senior Vice President and Chief Operations Officer, effective February 3, 2025. Peralta will oversee worldwide manufacturing operations, focusing on aligning operations with corporate goals, optimizing supply chain efficiency, and maintaining superior customer service.

With over 25 years of leadership experience, Peralta joins from Siemens Healthineers' ultrasound division, where he served as Vice President and Head of Global Operations. His track record includes successful transformations in supply chain processes and manufacturing operations at companies including Medtronic Diabetes, Hill-Rom, KCI Medical, and GE Healthcare.

The appointment comes at a strategic time for Accuray, following the company's recent expansion of its radiation therapy system portfolio. CEO Suzanne Winter emphasized that Peralta's expertise will be important in driving business growth while maintaining operational efficiency and customer satisfaction.

Accuray (NASDAQ: ARAY) announced the Chinese National Medical Products Administration (NMPA) approval of its Radixact SynC™ System and CyberKnife® S7™ System. This follows the recent approval of their Tomo C System in China. The approvals are strategically significant as China needs approximately 2,000 radiation therapy systems over the next five years.

The Radixact SynC System is the first helical delivery device in China featuring Synchrony real-time target tracking and ClearRT kVCT imaging technology. It delivers precise radiation doses through 360-degree rotations, with automatic adaptation to tumor movement. The CyberKnife S7 System provides sub-millimetric accuracy radiation treatments in just 1-5 outpatient sessions, completing procedures in as little as 15 minutes, compared to conventional 30-40 session treatments.